# Efficacy and Safety of Lobeglitazone Versus Sitagliptin

> **NCT02480465** · PHASE4 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 248 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Lobelitazone 0.5mg
- **DRUG:** Sitagliptin 100mg

## Key facts

- **NCT ID:** NCT02480465
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2016-12
- **Final completion:** 2017-03
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02480465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02480465, "Efficacy and Safety of Lobeglitazone Versus Sitagliptin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02480465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*